138 related articles for article (PubMed ID: 7447583)
21. Effect of duration of lidocaine infusion and route of cimetidine administration on lidocaine pharmacokinetics.
Powell JR; Foster J; Patterson JH; Cross R; Wargin W
Clin Pharm; 1986 Dec; 5(12):993-8. PubMed ID: 3802729
[TBL] [Abstract][Full Text] [Related]
22. Optimum dosage of lidocaine.
Laurikainen E; Arstila M; Pekkarinen A; Kanto J
Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):16-9. PubMed ID: 3988388
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of lidocaine kinetics in the isolated perfused rat liver. I. Effects of continuous infusion.
Tam YK; Yau M; Berzins R; Montgomery PR; Gray M
Drug Metab Dispos; 1987; 15(1):12-6. PubMed ID: 2881747
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic principles of lidocaine dosing in relation to disease state.
Waller ES
J Clin Pharmacol; 1981 Apr; 21(4):181-94. PubMed ID: 7240439
[TBL] [Abstract][Full Text] [Related]
25. Serum concentrations of lidocaine and its metabolites after prolonged infusion in healthy horses.
Dickey EJ; McKenzie HC; Brown KA; de Solis CN
Equine Vet J; 2008 Jun; 40(4):348-52. PubMed ID: 18267881
[TBL] [Abstract][Full Text] [Related]
26. [Serum concentration measurements for the monitoring of anti-arrhythmic therapy with lidocaine].
Follath F; Heierli B; Ganzinger U; Wenk M
Schweiz Med Wochenschr; 1980 Jun; 110(26):1007-10. PubMed ID: 6158756
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.
Wade M; Baker FJ; Roscigno R; DellaMaestra W; Arneson CP; Hunt TL; Lai AA
J Clin Pharmacol; 2004 May; 44(5):503-9. PubMed ID: 15102871
[TBL] [Abstract][Full Text] [Related]
28. [Study of a carrier solution for the lidocaine infusion therapy in myocardial infarct].
Junge O; Bickel H; Bartels O
Infusionsther Klin Ernahr; 1978 Aug; 5(4):209-12. PubMed ID: 567196
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion.
Estes NA; Manolis AS; Greenblatt DJ; Garan H; Ruskin JN
Am Heart J; 1989 May; 117(5):1060-4. PubMed ID: 2711965
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic lidocaine hydrochloride does not reduce ventricular arrhythmias after coronary artery bypass grafting in patients with poor left ventricular function.
Juneja R; Mehta Y; Trehan N
Indian Heart J; 1993; 45(6):483-7. PubMed ID: 8070826
[TBL] [Abstract][Full Text] [Related]
31. Plasma levels, protein binding, and elimination data of lidocaine and active metabolites in cardiac patients of various ages.
Drayer DE; Lorenzo B; Werns S; Reidenberg MM
Clin Pharmacol Ther; 1983 Jul; 34(1):14-22. PubMed ID: 6861434
[TBL] [Abstract][Full Text] [Related]
32. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure.
Mahgoub AA; El-Medany AH; Abdulatif AS
Saudi Med J; 2002 Jun; 23(6):725-31. PubMed ID: 12070557
[TBL] [Abstract][Full Text] [Related]
33. Influence of long-term infusions on lidocaine kinetics.
Bauer LA; Brown T; Gibaldi M; Hudson L; Nelson S; Raisys V; Shea JP
Clin Pharmacol Ther; 1982 Apr; 31(4):433-7. PubMed ID: 7060324
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
Chu KM; Shieh SM; Hu OY
Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
[TBL] [Abstract][Full Text] [Related]
36. Lignocaine kinetics in cardiac patients and aged subjects.
Nation RL; Triggs EJ; Selig M
Br J Clin Pharmacol; 1977 Aug; 4(4):439-48. PubMed ID: 901735
[TBL] [Abstract][Full Text] [Related]
37. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure.
Henderson KK; Danzi S; Paul JT; Leya G; Klein I; Samarel AM
Circ Heart Fail; 2009 May; 2(3):243-52. PubMed ID: 19808346
[TBL] [Abstract][Full Text] [Related]
38. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].
Wutte M; Hülsmann M; Berger R; Rödler S; Frey B; Stanek B; Pacher R
Wien Klin Wochenschr; 1998 Jul; 110(13-14):473-8. PubMed ID: 9746960
[TBL] [Abstract][Full Text] [Related]
39. Rapid estimation of unbound lidocaine clearance in cardiac patients: implications for reducing toxicity.
Denson DD; Toltzis RJ; Ernst TF; Youngs CH; Thomas RL; Grummich KW
J Clin Pharmacol; 1988 Nov; 28(11):995-1000. PubMed ID: 3243921
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent pharmacokinetic behavior of lidocaine in the conscious dog.
Vicuna N; Lalka D; Burrow SR; McLean AJ; du Souich P; McNay JL
Res Commun Chem Pathol Pharmacol; 1978 Dec; 22(3):485-91. PubMed ID: 734228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
